Survodutide Cuts Liver Fat in 84% of Phase 3 MASLD Patients as Weight Falls 12.2%
Updated
Updated · Nature.com · Jun 7
Survodutide Cuts Liver Fat in 84% of Phase 3 MASLD Patients as Weight Falls 12.2%
3 articles · Updated · Nature.com · Jun 7
Summary
In a 216-patient phase 3 trial, once-weekly survodutide 6.0 mg beat placebo on both main goals at 48 weeks in adults with obesity and at-risk MASLD.
84.2% of treated patients achieved at least a 30% liver-fat reduction versus 24.3% on placebo, while mean body weight fell 12.2% versus 1.0%; 61.0% also reached near-normal liver fat below 5%.
Liver and metabolic markers also improved, including VCTE-assessed liver stiffness, ALT, AST, waist circumference and blood pressure, though MRE-assessed stiffness did not differ between groups.
Gastrointestinal side effects were most common and led to discontinuation in 19.9% of survodutide patients versus 4.3% on placebo, but were generally mild to moderate and concentrated during dose escalation.
The 48-week study was limited to the United States and Spain and mostly early-stage disease, while broader phase 3 programs are still testing survodutide in more advanced MASH and cirrhosis.
One in five patients quit survodutide due to side effects. Can it truly compete if tolerability remains a major hurdle?
With a rival triple-agonist showing greater weight loss, can survodutide's liver benefits secure its market share?
Survodutide Achieves 84% Hepatic Fat Reduction in Phase 3 MASLD Trial: A New Era for Metabolic Liver Disease Treatment
Overview
The SYNCHRONIZE-MASLD Phase 3 study, involving 218 adults with obesity and metabolic-associated liver disease, revealed that survodutide significantly reduced liver fat, body weight, and visceral fat. Impressively, 84.2% of patients treated with survodutide achieved at least a 30% reduction in hepatic fat, highlighting its strong potential as a MASLD treatment. These results mark a crucial step forward, showing that survodutide’s efficacy could address key needs in managing this growing disease. The findings suggest that survodutide may become an important option for improving liver health and overall metabolic outcomes in affected patients.